Jason Kelly, chief executive of Ginkgo Bioworks, spent a surprising amount of time on an earnings call with analysts last ...

Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach wit ...

VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today ...

Explore SLAS Boston 2026 insights on connecting laboratory automation and data infrastructure in drug discovery workflows.

A letter writer's sister suggests that a lab-grown diamond isn't as special. How do you tell a loved one: "my ring is none of your business?" ...

Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and ...

A biotech slump and scrapped federal funds are stalling a decades-long expansion, being developed by Tishman Speyer.

More than 7 million Americans are living with Alzheimer's disease, the most common form of dementia. But there is research underway in Boston right now to ease that burden.

At Mass General Brigham, Boston researchers pair gene studies with a 12-point Brain Care Score to help lower the risk of Alzheimer's and other brain disorders.

Chinese biotechs are licensing assets to Western companies at record rates. Boston attorneys are racing to capture the dealmaking.

Hansen was drafted 26th overall in 2005 by Boston, which signed him to an MLB deal, and he debuted that September. He was ...